Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females~* Age ≥18 and ≤50 years at Screening~* HIV-1 seropositive~* asymptomatic and in generally good health~* no prior anti-retroviral therapy within 6 months of screening~* viral load ≥ 3,000 ≤ 100,000 HIV-1 RNA copies/mL~* CD4+ T-cell count ≥ 400/mm3.~Exclusion Criteria:~* Pregnant/nursing females~* positive for HBV or HCV~* acute Herpetic event~* any clinically significant out-of range laboratory value~* subject is unable or unwilling to discontinue during the study~* participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- TUTI-16 0.03 mg (Type: EXPERIMENTAL): Subcutaneous injection on Day 0, Day 28, and Day 84
- TUTI-16 0.1 mg (Type: EXPERIMENTAL): Subcutaneous injection on Day 0, Day 28, and Day 84
- TUTI-16 0.6 mg (Type: EXPERIMENTAL): Subcutaneous injection on Day 0, Day 28, and Day 84

Based on this trial design, predict the completion outcome and termination type (if applicable).